Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) experience in patients with recurrent low grade serous ovarian carcinoma (LGSOC): sub-cohort report of phase 1 clinical trial.

Saved in:
Bibliographic Details
Title: Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) experience in patients with recurrent low grade serous ovarian carcinoma (LGSOC): sub-cohort report of phase 1 clinical trial.
Authors: Nakamura B; Department of Surgery, City of Hope National Medical Center, Duarte, CA, United States., Senguttuvan R; Department of Surgery, City of Hope National Medical Center, Duarte, CA, United States., Ruel NH; Department of Computation and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA, United States., Frankel PH; Department of Computation and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA, United States., Yost SE; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, United States., Cole S; Clinical Protocol Development, City of Hope National Medical Center, Duarte, CA, United States., Chang S; Department of Pathology, City of Hope National Medical Center, Duarte, CA, United States., Jung A; Department of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA, United States., Eng M; Department of Surgery, City of Hope National Medical Center, Duarte, CA, United States., Tinsley R; Department of Surgery, City of Hope National Medical Center, Duarte, CA, United States., Stewart D; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, United States., Wang E; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, United States., Cohen J; Department of Surgery, City of Hope National Medical Center, Duarte, CA, United States., Villella J; Department of Surgery, Northwell Health, New York, NY, United States., Whelan RL; Department of Surgery, Northwell Health, New York, NY, United States., Merchea A; Department of Surgery, Mayo Clinic Florida, Jacksonville, FL, United States., DePeralta DK; Department of Surgery, Northwell Health, New York, NY, United States., Cristea M; Regeneron Pharmaceuticals, Tarrytown, NY, United States., Wakabayashi MT; Regeneron Pharmaceuticals, Tarrytown, NY, United States., Raoof M; Department of Surgery, City of Hope National Medical Center, Duarte, CA, United States., Dellinger TH; Department of Surgery, City of Hope National Medical Center, Duarte, CA, United States.
Source: Frontiers in oncology [Front Oncol] 2024 Aug 01; Vol. 14, pp. 1404936. Date of Electronic Publication: 2024 Aug 01 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2234-943X
DOI:10.3389/fonc.2024.1404936